The Oncology Institute, Inc. reaffirmed financial guidance for the year 2022. For the year, the company expects revenue to be in the range of $270 to $310 million, representing approximately 33% to 53% growth over 2021 revenue.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.45 USD | -3.02% |
|
-9.09% | -77.94% |
May. 14 | Transcript : The Oncology Institute, Inc., Q1 2024 Earnings Call, May 14, 2024 | |
May. 14 | The Oncology Institute, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
![Consensus](/images/consensus_flch.gif)
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-77.94% | 30.3M | |
+25.85% | 89.22B | |
-22.73% | 76.59B | |
+3.24% | 26.87B | |
-9.15% | 17.41B | |
+1.57% | 17.32B | |
-0.42% | 15.25B | |
+81.96% | 13.43B | |
+72.40% | 13.26B | |
-23.33% | 13.01B |
- Stock Market
- Equities
- TOI Stock
- News The Oncology Institute, Inc.
- The Oncology Institute, Inc. Reaffirms Financial Guidance for the Year 2022